Has David Jacobs, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,813 in general payments to David Jacobs, MD across 138 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Jacobs, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Jacobs, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Jacobs, MD

Ophthalmology · Richmond, VANPI 1184675100

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 25.4% of the total. 2025 is the largest year on record at $1,206, 5.6 times the $215 reported in 2021.

$3,813in general payments, 2019–2025

Across 138 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$969
Notal Vision, Inc.$554
Halozyme Inc$380
Genentech USA, Inc.$362
Alimera Sciences, Inc.$326
Regeneron Healthcare Solutions, Inc.$284
plus $938 from 11 others

$12,570in research payments, 2019–2025

Across 161 payments — averaging $78.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$6K
Notal Vision, Inc.$6K

What the payments were for

Speaking & faculty fees$38110%
Food & beverage$3,43290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	68	$969
Notal Vision, Inc.	9	$554
Halozyme Inc	1	$380
Genentech USA, Inc.	12	$362
Alimera Sciences, Inc.	7	$326
Regeneron Healthcare Solutions, Inc.	11	$284
Genentech, Inc.	2	$210
Mallinckrodt Hospital Products Inc.	6	$180
Apellis Pharmaceuticals, Inc.	2	$148
Astellas Pharma US Inc	4	$112
Bausch & Lomb Americas Inc.	5	$90
Alcon	4	$70
Harrow Eye, LLC	2	$38
ANI Pharmaceuticals, Inc.	2	$36
Eyepoint US, Inc.	1	$19
Carl Zeiss Meditec USA, Inc.	1	$18
Novartis	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,813 in reported general payments places this provider in the 80th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia →

Medicare billing

Part B allowed, 2024

$6,264,893

Medicare patients

1,401

Services billed

101,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	243	$9,926
Bromfenac Sodium	28	$4,612
Difluprednate	33	$3,645
Atropine Sulfate	124	$3,032
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	103	$1,797
Ketorolac Tromethamine	51	$1,374
Latanoprost	145	$975
Ofloxacin	87	$873
Timolol Maleate	57	$328
Brimonidine Tartrate	19	$108

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Richmond

Ethnie JonesRichmond$2M
Thomas JenkinsRichmond$26K
Jessica RandolphRichmond$18K
Nikisha RichardsRichmond$16K
Tam DangRichmond$9K
Byron LaddRichmond$7K
Bryan SchwentRichmond$7K
Rishi ParikhRichmond$6K
Elizabeth Yeu-LinNorfolk$1.7M
John SheppardNorfolk$1.1M

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →